| c-Met is a
receptor tyrosine kinase which
regulates cancer cell growth,
survival, angiogenesis, invasion
and metastasis. c-Met is an emerging
drug target, as through one target,
multiple therapeutic mechanisms
of action are interdicted. |
|
| Xcovery is
developing a small molecule inhibitor
of the c-Met kinase which is
currently in pre-clinical development. |
|
| The Xcovery
c-Met program -based on proprietary
chemical IP - is in the lead
optimization stage, with in vivo
PK data pending. |
|
Objective
|
To
discover potent and selective
c-Met inhibitors that can
induce significant conformational
changes in the receptor. |
Status
(April 2007)
|
| » |
Compounds
with nM potency have
been discovered |
| » |
>10x
selectivity against
a panel of 30 representative
kinases |
| |
» Excellent PK properties |
| |
» Excellent in vivo efficacy in multiple models |
| » |
Provisional
patent application
filed in Jan. 2007 |
|
| Next
Milestone |
Cell
activity and PK by early
summer, 2007 |
| |
Preclinical Candidate by Q3 2008 |
|
| |
|